JP2023504547A5 - - Google Patents

Info

Publication number
JP2023504547A5
JP2023504547A5 JP2022533470A JP2022533470A JP2023504547A5 JP 2023504547 A5 JP2023504547 A5 JP 2023504547A5 JP 2022533470 A JP2022533470 A JP 2022533470A JP 2022533470 A JP2022533470 A JP 2022533470A JP 2023504547 A5 JP2023504547 A5 JP 2023504547A5
Authority
JP
Japan
Prior art keywords
composition according
subject
dosage form
unit dosage
active agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022533470A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023504547A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/063281 external-priority patent/WO2021113620A1/en
Publication of JP2023504547A publication Critical patent/JP2023504547A/ja
Publication of JP2023504547A5 publication Critical patent/JP2023504547A5/ja
Pending legal-status Critical Current

Links

JP2022533470A 2019-12-05 2020-12-04 アシル化された活性薬剤並びに代謝異常及び非アルコール性脂肪性肝疾患の治療のためのそれらの使用の方法 Pending JP2023504547A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962944282P 2019-12-05 2019-12-05
US62/944,282 2019-12-05
US202063074785P 2020-09-04 2020-09-04
US63/074,785 2020-09-04
PCT/US2020/063281 WO2021113620A1 (en) 2019-12-05 2020-12-04 Acylated active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease

Publications (2)

Publication Number Publication Date
JP2023504547A JP2023504547A (ja) 2023-02-03
JP2023504547A5 true JP2023504547A5 (enExample) 2023-12-11

Family

ID=76221219

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022533470A Pending JP2023504547A (ja) 2019-12-05 2020-12-04 アシル化された活性薬剤並びに代謝異常及び非アルコール性脂肪性肝疾患の治療のためのそれらの使用の方法

Country Status (8)

Country Link
US (1) US20220296563A1 (enExample)
EP (1) EP4069209A4 (enExample)
JP (1) JP2023504547A (enExample)
CN (1) CN114901267A (enExample)
AU (1) AU2020396554A1 (enExample)
BR (1) BR112022010672A2 (enExample)
CA (1) CA3163342A1 (enExample)
WO (1) WO2021113620A1 (enExample)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2258173A1 (en) * 1974-01-22 1975-08-18 Expl Marques Brevets Et Acetylsalicylic acid 2-p-chlorophenoxy isobutyric acid compsns - with anticoagulant and hypocholesterolaemic effects
US4276430A (en) * 1976-12-15 1981-06-30 The Procter & Gamble Company Analgesic and anti-inflammatory compounds and compositions containing same
US4339428A (en) * 1980-08-18 1982-07-13 Bristol-Myers Company Capsule product containing high dosage of aspirin in powder or granulated form and alkaline tablet or pellet comprising magnesium carbonate, calcium carbonate and a magnesium dry component
FR2720936B1 (fr) * 1994-06-08 1997-04-30 Synthelabo Poudres à base de métoclopramide et de paracétamol ou de dérivés d'acide acétylsalicylique.
MX9704079A (es) * 1994-12-01 1997-12-31 Cibus Pharmaceutical Inc Liberacion de farmacos antiinflamatorios no esteroides empleando uan goam hidrocoloide en polvo que se obtiene de plantas superiores.
DE19726871C1 (de) * 1997-06-24 1999-03-04 Werner Kreutz Synergistisch wirkende Zusammensetzungen zur selektiven Bekämpfung von Tumorgewebe
US20090036516A1 (en) * 2003-01-13 2009-02-05 Ctg Pharma S.R.L. Compounds for treating metabolic syndrome
US20080114075A1 (en) * 2006-08-16 2008-05-15 Action Medicines Use of 2,5-Dihydroxybenzene Derivatives for Treating Dermatitis
NZ597534A (en) * 2009-06-25 2013-09-27 Pozen Inc Method for treating a patient in need of aspirin therapy
EP2588108A2 (en) * 2010-07-02 2013-05-08 Solvotrin Therapeutics Ltd. Treatment for dyslipidemia
US8287904B2 (en) * 2010-08-19 2012-10-16 Lionel Borkan Stable soft capsule dosage form for acetylsalicylic acid
US11771659B2 (en) * 2017-06-19 2023-10-03 The Cleveland Clinic Foundation Treating disease and promoting weight loss by inhibiting the TMA/FMO3/TMAO pathway
JP2021528385A (ja) * 2018-06-05 2021-10-21 フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド 自己免疫障害を治療するためのアシル化活性剤およびその使用方法
EP3801496A4 (en) * 2018-06-05 2022-07-06 Flagship Pioneering Innovations V, Inc. SUBSTANCES AND METHODS OF USE FOR THE TREATMENT OF METABOLIC DISEASES AND NON-ALCOHOL FATTY LIVER
JP7645244B2 (ja) * 2019-08-30 2025-03-13 中国科学院動物研究所 代謝性疾患と闘うために使用される組成物およびその組成物の使用

Similar Documents

Publication Publication Date Title
CN103338762B (zh) 血糖值上升抑制剂
JP2021528384A5 (enExample)
Lewis et al. Effects of jejunocolic shunt on obesity, serum lipoproteins, lipids, and electrolytes
EP3723511A1 (en) Compositions and methods for weight loss maintenance
JP2009173634A (ja) ポリ−γ−グルタミン酸を含有する脂質吸収阻害剤
WO2020009111A1 (ja) 脂肪蓄積抑制用組成物
US20020193430A1 (en) Correcting polymorphic metabolic dysfunction with (-)- hydroxycitric acid
JP2022524962A (ja) 中鎖トリグリセリドの食前投与により食事に由来する食後血糖を低減する方法
WO2007049818A1 (ja) 抗脂肪肝、抗肥満及び抗高脂血症用組成物
JPWO2007114499A1 (ja) 抗脂肪蓄積用組成物
JP7271693B2 (ja) ハイドロキノン誘導体を含む肥満又は非アルコール性脂肪肝炎の予防又は治療用薬学組成物
CN1777417B (zh) PPARα激动剂和二甲双胍降低血清甘油三酯的用途
WO2022230920A1 (ja) 血中カルニチン増加剤
HK1257401A1 (zh) 用於治疗糖尿病和相关病症的方法和组合物
JP4139544B2 (ja) 血糖値低下剤
JP2023505233A5 (enExample)
AU2021336289A1 (en) Ionic liquid formulations for treating diabetes
WO2018102914A1 (en) Use of medium-chain triglycerides for the management of metabolic conditions
JP3029907B2 (ja) 抗肥満剤
CN1452482A (zh) 含有胆碱和琥珀酸用于治疗胰岛素抵抗和糖尿病的协同组成物
WO2013005834A1 (ja) 高純度ｅｐａを含有する抗肥満剤
JP5576699B2 (ja) Ｇｉｐ上昇抑制剤
EP1156795A1 (en) Use of succinic acid or salts thereof and method of treating insulin resistance
JPWO2007069744A1 (ja) メタボリックシンドローム予防・改善用組成物
EP1219297A1 (en) Antiobestic agents